Quadmedison Signs Joint Research Agreement with GSK Vaccine Institute

Preparing for KOSDAQ Listing with IPO Underwriter NH Investment & Securities

[Asia Economy Reporter Hyungsoo Park] QuadMedicine, a medical microneedle platform company preparing for listing on the KOSDAQ market, announced on the 4th that it has signed a joint vaccine research and material transfer agreement with GVGH.

GVGH is a vaccine research institute operated by the global pharmaceutical company GSK. It researches and develops vaccines for the prevention and treatment of infectious diseases in low- and middle-income countries.

According to the joint research and material transfer agreement, QuadMedicine will receive vaccines under development from GVGH and conduct research on vaccine microneedles. Based on the results of the joint research, additional contracts for process development and clinical research are also expected to be possible.

QuadMedicine possesses a medical microneedle platform technology applicable to transdermally deliverable vaccine drugs, synthetic drugs, and diagnostic medical devices. Microneedles are convergent medical products combining pharmaceuticals and medical devices, minimizing side effects of existing subcutaneous injections or oral medications. They also enhance patient convenience.

Seunggi Baek, CEO of QuadMedicine, stated, "The bio and medical device industries are paying attention to microneedle product development," adding, "We hope to contribute to global public health improvement through cooperation with domestic and international institutions."

Since 2020, QuadMedicine has been developing hepatitis B vaccine microneedles through a joint research and development contract with LG Chem. They are also co-developing pentavalent combination vaccine microneedles. Recently, they have started developing COVID-19 mRNA vaccine microneedles. They are developing quadrivalent influenza vaccine microneedles with Ilyang Pharmaceutical. Earlier this year, they licensed technology for osteoporosis treatment using microneedles to Hallim Pharmaceutical, the first case in Korea. They have signed a listing underwriting contract with NH Investment & Securities and are also pursuing listing on the KOSDAQ market.